- Home
- EDU vs HALO Comparison
EDU vs HALO Comparison
Compare EDU & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | HALO |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | China | United States |
| Employees | 84111 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.8B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | EDU | HALO |
|---|---|---|
| Price | $50.88 | $67.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $62.80 | ★ $78.64 |
| AVG Volume (30 Days) | 718.2K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $12.83 | $28.24 |
| Revenue Next Year | $11.16 | $12.56 |
| P/E Ratio | ★ $24.75 | $56.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.62 | $51.06 |
| 52 Week High | $64.97 | $82.22 |
Technical Indicators
Market Signals| Indicator | EDU | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 52.10 |
| Support Level | $50.47 | $62.53 |
| Resistance Level | $54.97 | $70.93 |
| Average True Range (ATR) | 1.29 | 2.67 |
| MACD | -0.26 | 0.43 |
| Stochastic Oscillator | 11.14 | 42.57 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.